Back to results
US 2022/0016082 A1Published application
Combination therapies for high and very high risk mds
AssigneeMEI Pharma, Inc.
InventorRichard GHALIE
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating high and very high risk MDS comprising administering pracinostat and a DNA hypomethylating agent. S
Claims48
A method of treating high or very high risk myelodysplastic syndromes (MDS) in a patient in need thereof, the method comprising administering to the patient:
- (i) a DNA hypomethylating agent;
- and
- (ii) about 45 mg of a compound of formula (I):
- wherein
- R1 is —(CR20R21)m—(CR22R23)n—(CR24R25)o—NR26R27;
- R2 is alkyl, fluoroalkyl, cyano, C2-C6alkenyl, C2-C6alkynyl, or heteroalkyl optionally substituted with ═O;
- each R20, R21, R22, R23, R24, and R25 is independently H or methyl;
- each R26 and R27 is independently H, hydroxyalkyl, or alkyl;
- and
- m, n, and o are independently integers of 0, 1, 2, 3, or 4;
- or a pharmaceutically acceptable salt, isotopic variant, or prodrug thereof.
8 more elements
A method of treating high or very high risk myelodysplastic syndromes (MDS) in a patient in need thereof, the method comprising administering to the patient:
- (i) a DNA hypomethylating agent;
- and
- (ii) about 45 mg of pracinostat, or a pharmaceutically acceptable salt, isotopic variant, or prodrug thereof, wherein pracinostat is orally administered to the patient 3 days each week for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.
A method of treating high or very high risk myelodysplastic syndromes (MDS) in a patient in need thereof, the method comprising administering to the patient:
- (i) about 75 mg/m2 of 5-azacytidine (azacitidine), wherein 5-azacytidine (azacitidine) is administered intravenously or subcutaneously for 7 days of each 28-day cycle;
- and
- (ii) about 45 mg of pracinostat, or a pharmaceutically acceptable salt, isotopic variant, or prodrug thereof, wherein pracinostat is orally administered for 3 days each week for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.
Dependencies are inferred from the claim text.